Answers are grounded in this paper and cite their sources.
The study demonstrates how receptor agonists affect adipogenesis in thyroid eye disease, suggesting a potential therapeutic approach.
Activation of EP3, FP, and EP2 receptors differentially modulates orbital adipogenesis. Among them, EP3 receptor activation by sulprostone suppresses adipogenic differentiation without increasing the evaluated inflammatory cytokines in our study. These findings suggest that EP3 receptor agonism may represent a potential strategy for limiting orbital fat expansion in TED, although further in vivo studies are required to evaluate its therapeutic feasibility and safety.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: